E. Téllez

Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

G. Cervantes, P. Cortes, L. Pérez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study

O. Arrieta, J. G. De la Garza, Sergio A Treviño, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Wood-smoke exposure as a survival predictor in non-small cell lung cancer with response to erlotinib: an open label phase II study: P3-062

O. Arrieta, J. Garza, R. Morales-Barrera, 2007 .

Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]).

R. Greil, S. Barni, D. Miles, 2009 .